Fintel reports that on July 21, 2023, Cantor Fitzgerald reiterated coverage of Kura Oncology (NASDAQ:KURA) with a Overweight recommendation.
Analyst Price Forecast Suggests 197.38% Upside
As of July 6, 2023, the average one-year price target for Kura Oncology is 32.74. The forecasts range from a low of 22.22 to a high of $49.35. The average price target represents an increase of 197.38% from its latest reported closing price of 11.01.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Kura Oncology is 0MM. The projected annual non-GAAP EPS is -2.50.
What is the Fund Sentiment?
There are 353 funds or institutions reporting positions in Kura Oncology. This is an increase of 7 owner(s) or 2.02% in the last quarter. Average portfolio weight of all funds dedicated to KURA is 0.17%, an increase of 31.75%. Total shares owned by institutions increased in the last three months by 2.96% to 78,006K shares. The put/call ratio of KURA is 0.21, indicating a bullish outlook.
What are Other Shareholders Doing?

Bvf holds 6,731K shares representing 9.84% ownership of the company. In it's prior filing, the firm reported owning 3,801K shares, representing an increase of 43.53%. The firm increased its portfolio allocation in KURA by 51.16% over the last quarter.
EcoR1 Capital holds 6,638K shares representing 9.70% ownership of the company. No change in the last quarter.
Suvretta Capital Management holds 6,573K shares representing 9.60% ownership of the company. In it's prior filing, the firm reported owning 6,377K shares, representing an increase of 2.99%. The firm increased its portfolio allocation in KURA by 2.17% over the last quarter.
Avoro Capital Advisors holds 3,105K shares representing 4.54% ownership of the company. No change in the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 2,546K shares representing 3.72% ownership of the company. In it's prior filing, the firm reported owning 3,165K shares, representing a decrease of 24.30%. The firm decreased its portfolio allocation in KURA by 0.96% over the last quarter.
Kura Oncology Background Information
(This description is provided by the company.)
Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology
Additional reading:
- KURA ONCOLOGY, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK
- Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
- Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
- This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and K
- Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board: March 6, 2015 Approved by the Stockholders: March 6, 2015 Amended by the Board: September 26, 2022 and April 4, 2023 Approved by the Stockholders:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.